Seroprevalence of Human Parainfluenza Virus Types 1-4 Among Healthy Children Under 5 Years of Age in Korea
| Autor: | KimJong-Hyun, ChoiUi Yoon, LeeSoo Young, LeeJoo Young, KangJin Han, ParkGeunha |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male viruses 030106 microbiology Immunology Antibodies Viral Respirovirus Infections Respirovirus 03 medical and health sciences Seroepidemiologic Studies Virology Republic of Korea Seroprevalence Medicine Humans Respiratory Tract Infections business.industry Infant Rubulavirus Infections Hemagglutination Inhibition Tests Human Parainfluenza Virus Cross-Sectional Studies Rubulavirus Child Preschool Molecular Medicine Female business |
| Zdroj: | Viral immunology. 31(5) |
| ISSN: | 1557-8976 |
| Popis: | Human parainfluenza viruses (HPIVs) are among the major causes of respiratory infections in children, worldwide, including in Korea. There are four types of HPIVs, each with different epidemiological characteristics. HPIV3 is the most frequently circulating HPIV type, while the epidemiology of HPIV4 remains unclear. The aim of this study was to investigate the age-stratified seropositivity rates of HPIV types 1-4 among children in Korea. These data will be useful to determine vaccine requirements. This study included 245 participants categorized into four age groups: 6-11 months, 1 year, 2 years, and 3-5 years. Hemagglutination inhibition (HAI) assay was used to measure the antibody titers in the serum samples of the subjects. Overall, a significantly higher seropositivity rate (68%) was observed for HPIV3 (p 0.001), indicating the predominant circulation of this type. In the 3- to 5-year-old group, 97% of the participants displayed seropositivity for HPIV3, suggesting that most Korean children acquire HPIV3 infection by the age of 5 years. The seropositivity rate for HPIV3 increased with age (p 0.001); a prompt rise was observed between the 6-11 months age group and the 1-year age group. The seropositivity rates of HPIV1, HPIV2, and HPIV4 were found to increase with age (p 0.001), with a marked increase recorded after the age of 2 years. HPIV1, HPIV2, and HPIV4 tended to infect children later than HPIV3. Older children showed high antibody titer ranges for HPIV3 (p 0.001), suggesting that children experience multiple HPIV3 infections. An increasing trend of HPIV4 seropositivity rates with age was observed and this was comparable to theHPIV1 and HPIV2 seropositivity rates, indicating that its incidence may have been underestimated. To reduce HPIV infection, the administration of a HPIV3 vaccine to children 1 year of age is likely to be the most effective option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|